首页> 美国卫生研究院文献>Mediators of Inflammation >Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo.
【2h】

Suppressive effects of anti-allergic agent suplatast tosilate (IPD-1151T) on the expression of co-stimulatory molecules on mouse splenocytes in vivo.

机译:体内抗过敏药物suplateast tolateate(IPD-1151T)对小鼠脾细胞共刺激分子表达的抑制作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The effects of IPD-1151T on the expression of co-stimulatory molecules, CD40, CD80 and CD86, were investigated in vivo using mice with allergic disorders. BALB/c mice were immunized intraperitoneally with two doses of dinitrophenylated ovalbumin (DNP-OVA) at 1-week intervals. These mice then were treated intraperitoneally with 100 microg/kg of IPD-1151T once a day for 14 days, starting 7 days after the first immunization. On day 21, some mice were challenged intraperitoneally with DNP-OVA and the other mice were not challenged. All mice were autopsied on day 22 and assayed for immunoglobulin E, interleuken (IL)-4 and IL-5 productions following DNP-OVA immunization. The intraperitoneal treatment with IPD-1151T strongly suppressed immunoglobulin E contents in serum, which were enhanced by DNA-OVA immunization. IPD-1151T also caused a decrease in both IL-4 and IL-5 levels in splenic lymphocytes. We next examined the influence of IPD-1151T on co-stimulatory molecule expression on splenic lymphocytes. IPD-1151T caused suppression of CD40 and CD86 expression; however, the treatments did not affect CD80 expression.
机译:使用患有过敏性疾病的小鼠体内研究了IPD-1151T对共刺激分子CD40,CD80和CD86表达的影响。以1周的间隔用两次剂量的二硝基苯基化卵清蛋白(DNP-OVA)腹膜内免疫BALB / c小鼠。然后,从第一次免疫后的7天开始,每天一次用100 microg / kg IPD-1151T腹膜内处理这些小鼠,持续14天。在第21天,用DNP-OVA腹膜内攻击一些小鼠,而其他小鼠不攻击。在第22天对所有小鼠进行尸检,并在DNP-OVA免疫后测定免疫球蛋白E,白细胞介素(IL)-4和IL-5的产生。 IPD-1151T腹膜内处理可强烈抑制血清中的免疫球蛋白E含量,而DNA-OVA免疫可提高这些含量。 IPD-1151T还导致脾淋巴细胞的IL-4和IL-5水平降低。接下来,我们检查了IPD-1151T对脾淋巴细胞共刺激分子表达的影响。 IPD-1151T抑制CD40和CD86表达;然而,这些治疗并不影响CD80的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号